Results 191 to 200 of about 25,240 (222)

A novel class of 5-HT2a receptor antagonists: Aryl aminoguanidines

Life Sciences, 1996
Local delivery of serotonin (5-HT) produces a rapid edematous response in soft tissues via increased fluid extravasation which is prevented by 5-HT2 antagonists such as ketanserin or mianserin. Here we report the effects of a new class of aminoguanidine 5-HT2 antagonists, with relative selectivity for 5-HT2A receptors which are potent inhibitors of 5 ...
H U, Bryant, D L, Nelson, D, Button, H W, Cole, M B, Baez, V L, Lucaites, D B, Wainscott, C, Whitesitt, J, Reel, R, Simon, G A, Koppel   +10 more
openaire   +2 more sources

Role of Serotonin2A (5-HT2A) Receptors in Epilepsy

2018
5-Hydroxytryptamine 2A receptors (5-HT2ARs), have been implicated in various psychiatric and neurological disorders, including epilepsy. Interestingly, epileptic patients commonly present comorbid psychiatric symptoms, and a bidirectional link between depression and epilepsy has been suggested.
Vincenzo Crunelli, Marcello Venzi, Philippe De Deurwaerdère, Giuseppe Di Giovanni   +3 more
openaire   +1 more source

Serotonergic Receptor 5-HT2A in the Cardiosympathovagal System

2018
The serotonin receptor 5-HT2A is widely expressed throughout the central nervous system. While abundant evidence exits implicating 5-HT2A receptors in regulating central nervous system, in particular stress responses and that their expression levels or signaling can contribute to stress-related disorders such as anxiety, depression and aggression; the ...
M. Kermorgant, A. Pavy-Le Traon, J. M. Senard, D. N. Arvanitis   +3 more
openaire   +1 more source

Neuropharmacological Advances: Harnessing 5-HT2A Receptor Modulators and Psychoplastogens

ACS Medicinal Chemistry Letters
This Patent Highlight explores the emerging role of 5-HT2A receptor modulators and psychoplastogens in neuropsychiatric treatment. It delves into these novel compounds' molecular mechanisms, therapeutic potential, and challenges, highlighting their therapeutic potential in mental health care.
openaire   +2 more sources

Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity

Nature, 2022
Anat Levit, Jeffrey F Diberto, Ramona Rodriguiz   +2 more
exaly  

5-HT2A Receptor

2010
Michael H. Bloch, Michael H. Bloch, Mark A. Geyer, David C. S. Roberts, Eileen M. Joyce, Jonathan P. Roiser, John H. Halpern, Joji Suzuki, Pedro E. Huertas, Torsten Passie, John H. Halpern, Joji Suzuki, Pedro E. Huertas, Torsten Passie, Joji Suzuki, Torsten Passie, Pedro E. Huertas, John H. Halpern, Joji Suzuki, Torsten Passie, Pedro E. Huertas, John H. Halpern, David E. Nichols, Marie-Louise G. Wadenberg, Trevor W. Robbins, David S. Baldwin, Sophie Tambour, John C. Crabbe, Lucio Tremolizzo, Gessica Sala, Carlo Ferrarese, Brian L. Odlaug, Jon E. Grant, Paul D. Callaghan, Iain S. McGregor, Murray R. Thompson, Sarah Morgan, Angus Mackay, E. Ernst, Lawrence H. Price, Michael M. Morgan, MacDonald J. Christie, Susan Jones, Andrew Young, Elizabeth C. Warburton, Stephen J. Hill, Anthony R. Isles, Lawrence S. Wilkinson, Subhash C. Pandey, Subhash C. Pandey, Subhash C. Pandey, Aldo Badiani, James Winslow, Susan Jones, Jill B. Becker, Lucio Tremolizzo, Gessica Sala, Carlo Ferrarese, Paul D. Callaghan, Iain S. McGregor, Murray R. Thompson, David E. Nichols, Jason C. G. Halford, Stephen B. Dunnett, Martine Cador, Naheed (Max) Mirza, Andrea Bari, Yesne Alici, William Breitbart, Andrea Bari, Becky Kinkead, Charles B. Nemeroff, Lucy C. Guillory, Jason C. G. Halford, Ennio Esposito, William Invernizzi, Gary Remington, Tomasz Schneider, Michel Billiard, Michel Billiard, Alyson J. Bond, Paolo Nencini, Michele S. Milella, Brian E. Leonard, Yesne Alici, William Breitbart, Luis de Lecea, Michel Billiard, Samuel B. Hutton, Jason C. G. Halford, R. H. De Rijk, E. R. de Kloet, Tooru M. Mizuno, Maria Isabel Colado, A. Richard Green   +94 more
openaire   +1 more source

5-HT1A receptor sensitivity after 5-HT2A receptor downregulation

Biological Psychiatry, 1996
J.G. Hensler, K.A. Truett
openaire   +1 more source

Intact 5-HT2A receptor gene in schizophrenia

European Neuropsychopharmacology, 1996
K. Ohara, T. Ishigaki, D.-W. Xie, Y. Nakamura, K. Tani, K. Miyasato, K. Ohara   +6 more
openaire   +1 more source

ACP-103, a 5-HT2A receptor inverse agonist.

Current opinion in investigational drugs (London, England : 2000), 2006
ACADIA Pharmaceuticals is developing ACP-103, lead compound in a series of 5-HT2A inverse agonists, as a potential antipsychotic agent and for the potential treatment of insomnia. Phase II clinical trials in treatment-induced psychosis in Parkinson's disease (PD) patients and in schizophrenic patients are ongoing, as are phase II trials evaluating the ...
openaire   +1 more source

5-HT2A/2B/2C Receptor

2014
openaire   +1 more source